Skip Navigation LinksSkip Navigation Links
Centers for Disease Control and Prevention
Safer Healthier People
Blue White
Blue White
bottom curve
CDC Home Search Health Topics A-Z spacer spacer
spacer
Blue curve MMWR spacer
spacer
spacer

The content on this page is being archived for historic and reference purposes only. The content, links, and pdfs are no longer maintained and might be outdated.

Notice to Readers: Recall of Isoniazid Used for Antimicrobial Susceptibility Testing for Tuberculosis

Becton Dickinson Biosciences (Sparks, Maryland) has issued a voluntary recall of a lot of isoniazid [INH] (drug lot no. 9335260) used for antimicrobial susceptibility testing (AST) of Mycobacterium tuberculosis. The recalled INH lot was sold as components of BACTEC™* S.I.R.E. kits (lot nos. 9327296, 9342298, and 9327298) and as individual drug for reconstitution (BACTEC™ Isoniazid kit lot no. 9327297) during January 2000--August 25, 2000.

The recall was issued following customer complaints and subsequent investigations by the manufacturer that found that vials of streptomycin may have been labeled inadvertently as the recalled lot of INH. A second lot of INH (drug lot no. 0077261) that was implicated initially is no longer involved in the recall. In the original complaint involving lot no. 0077261, the incorrect lot number was reported to the manufacturer. This recall does not affect other sources of INH used for AST or for therapeutic purposes.

Laboratories that perform AST for M. tuberculosis should identify all isolates on which INH AST was performed with the recalled lot of INH. The results of tests with recalled INH are unreliable, potentially yielding falsely susceptible or falsely resistent results. These test results should be confirmed by a second test using nonrecalled INH on the same isolate or on a subsequent isolate obtained from the patient. Clinicians caring for patients with isolates requiring repeat testing should be notified of the recall and the possibility of erroneous INH AST results. If necessary, laboratories should consult with clinicians to prioritize repeat INH AST testing as follows: 1) immediately retest isolates from patients who have not responded to antituberculosis therapy as expected; 2) retest isolates for which any other first-line antituberculosis drug resistance was observed; 3) retest isolates from patients still receiving induction phase therapy; and 4) retest remaining isolates for which INH AST is unreliable.

Clinicians and patients using the standard 6-month four-drug regimen for tuberculosis (1) should be reassured because 1) in the United States, most patients are treated successfully with this regimen; 2) most patients are infected with strains of M. tuberculosis that are susceptible to all first-line antituberculosis drugs (2); and 3) results from controlled clinical trials indicate that this regimen is effective for patients infected with INH monoresistant M. tuberculosis (3). Therefore, patients who have completed this regimen and who have been discharged as cured before repeat AST results are available do not need additional drug therapy even if INH resistance is subsequently identified. Patients found to have INH monoresistant organisms after induction therapy is complete (e.g., during continuation phase of therapy with INH and rifampin) should be evaluated for treatment failure clinically and with cultures. Patients with an acceptable clinical course and no evidence of treatment failure could complete the continuation phase with INH and rifampin. In both instances, patients should be screened clinically for recurrent tuberculosis at 3, 6, and 12 months after completion of therapy and, if relapse is suspected, cultures should be obtained.

Patients who are identified as infected with INH monoresistant organisms before the induction phase of therapy is completed may be treated with a combination of rifampin, pyrazinamide, and ethambutol (or streptomycin) for 6 months. INH also may be included if repeat AST is resistant to INH at low levels (e.g., 0.1 µg/mL BACTEC™ media, or 0.2 µg/mL 7H10 media) but is not resistant at high levels (e.g., 0.4 µg/mL BACTEC™ media, or 1 µg/mL 7H10 media). Antituberculosis therapy and monitoring should be individualized for patients treated with other regimens, for patients who have not responded to therapy as expected, or for patients infected with M. tuberculosis strains resistant to one or more drugs in addition to INH. Patients with unrecognized INH monoresistance who were treated with the two-drug regimen of INH and rifampin and those treated initially with INH, rifampin, and pyrazinamide are at increased risk for treatment failure and/or relapse after treatment, possibly associated with acquired rifampin resistance. If a change in the treatment regimen is considered necessary, the initial regimen should be augmented with at least two additional drugs to which the patient's M. tuberculosis isolate has been proven susceptible and, if possible, which the patient has not received previously.

References

  1. Bass JB, Farer LS, Hopewell R, et al. Treatment of tuberculosis and tuberculosis infection in adults and children. Am J Respir Crit Care Med 1994;149:1359--74.
  2. Moore M, Onorato IM, McCray E, Castro KG. Trends in drug-resistant tuberculosis in the United States, 1993--1996. JAMA 1997;278:833--7.
  3. Mitchison DA, Nunn AJ. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis 1986;133:423--30.

* Use of trade names and commercial sources is for identification only and does not constitute endorsement by CDC or the U.S. Department of Health and Human Services.

Disclaimer   All MMWR HTML versions of articles are electronic conversions from ASCII text into HTML. This conversion may have resulted in character translation or format errors in the HTML version. Users should not rely on this HTML document, but are referred to the electronic PDF version and/or the original MMWR paper copy for the official text, figures, and tables. An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800. Contact GPO for current prices.

**Questions or messages regarding errors in formatting should be addressed to mmwrq@cdc.gov.

Page converted: 8/31/2000

HOME  |  ABOUT MMWR  |  MMWR SEARCH  |  DOWNLOADS  |  RSSCONTACT
POLICY  |  DISCLAIMER  |  ACCESSIBILITY

Safer, Healthier People

Morbidity and Mortality Weekly Report
Centers for Disease Control and Prevention
1600 Clifton Rd, MailStop E-90, Atlanta, GA 30333, U.S.A

USA.GovDHHS

Department of Health
and Human Services

This page last reviewed 5/2/01